Design, Synthesis, and Biological Evaluation of 2-Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors (Q58862225)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Angela Nebbioso

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Lucia Altucci

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Saverio Cellamare

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Manfred Jung

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1

Diana A Stolfa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

8

Angelo Carotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Julia M Gajer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

24 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

1256-1266

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

Epigenetics in cancer: targeting chromatin modifications

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Cancer epigenomics: DNA methylomes and histone-modification maps

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Epigenetic Targets in Drug Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Histone modifications: signalling receptors and potential elements of a heritable epigenetic code

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

21 January 2018

Memorable transcription

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Unraveling the epigenetic code of cancer for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Histone acetyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

The human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Inside HDAC with HDAC inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

The class‐I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6‐independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Phenylglycine and phenylalanine derivatives as potent and selective HDAC1 inhibitors (SHI-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Discovery of a Novel Class of Potent Coumarin Monoamine Oxidase B Inhibitors: Development and Biopharmacological Profiling of 7-[(3-Chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one Methanesulfonate (NW-1772) as a Highly Potent, Selective, R

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

In vitro assays for the determination of histone deacetylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Palladium-catalyzed cross-coupling reactions of pyridylboronic acids with heteroaryl halides bearing a primary amine group: synthesis of highly substituted bipyridines and pyrazinopyridines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: new potent non-competitive metabotropic glutamate receptor 2/3 antagonists. Part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Subtype selective substrates for histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

Cancer epigenetics is no Mickey Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

7 January 2021

Epigenetics and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

7 January 2021

Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

7 January 2021

Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

7 January 2021

NMR study of 1:1 complexes between divalent sulfur and aromatic compounds: a model for interactions in globular proteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

7 January 2021

Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200193

7 January 2021

Identifiers

DOI

10.1002/CMDC.201200193

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22628266%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference